The International Committee of Medical Journal Editors (ICMJE) recently reiterated its commitment to improving trial transparency by sharing individual patient data from randomised trials.
1 2 But, although sharing individual patient data contributes to transparency, it is not sufficient by itself. Trial transparency requires a data sharing package, which begins with trial registration and contains other elements such as protocols, summary results, and other trial materials.
Valuable as sharing individual patient data can be, 3 discussion about it has hijacked the broader conversation about data sharing and trial transparency. [4] [5] [6] For example, we identified 76 articles published in the six leading general medical journals that had "data" and "sharing" in their title and were about clinical trials. In 64 (84%) articles, the content was focused on individual patient data and did not mention any of the other components of trial transparency (see appendix on bmj.com).
Much of the discussion has focused on the complexities and practical problems associated with sharing individual patient data and on the processes and systems needed for responsible data sharing. [6] [7] [8] [9] However, many of the data sharing activities that are needed for trial transparency are not complex. We believe that trying to solve the complex issues around availability of individual patient data should not eclipse or distract from a more pressing problem: the unavailability of even summary data and protocols from all controlled trials. Current estimates are that around 85% of research is avoidably "wasted" because of design flaws, poor conduct, non-publication, and poor reporting. 10 Focusing efforts and attention on making individual patient data accessible might paradoxically exacerbate this waste in research. We argue that simpler and more cost efficient activities should be prioritised.
Our suggestions ( fig 1⇓) expand on a previously published trial reporting system.
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Trial transparency priorities
Prospective trial registration
About half of trials are never published. 12 In 2005 the ICMJE introduced prospective registration as an attempt to minimise selective reporting. However, many trials are still not prospectively registered, even those published in high impact journals, 13 and fewer than half of the journals that publish reports of trials enforce this requirement.
14 As well as the problems of selective publication of trials and outcomes, unregistered trials, or those registered after the completion date, tend to yield larger estimates of treatment effects than those registered before completion. 15 Trial registration is simple, inexpensive, and uses existing systems such as ClinicalTrials.gov. The AllTrials campaign has been championing trial registration for all trials, as well as calling for summary results and a full report (full methods, analyses, and results) to be publicly available, but the campaign has stated explicitly: "We do not call for individual patient data to be made publicly available." 16 The campaign has also highlighted ways in which trial registration could be improved. Although the World Health Organization has fostered the development of an international standard for trial registration data, 17 minimum requirements are neither sufficient nor enforced. trials of approved medicines with at least one site in the US or conducted as part of a marketing approval application) be submitted within 12 months of the completion of data collection, whether or not the trial had been formally published in a journal. The information required includes tabular summaries of participant flow, baseline characteristics, prespecified outcome data and adverse events by study arm or comparison group, and statistical analyses. However, subsequent audits have shown that only about a fifth of trials comply. 18 Furthermore, although the FDA is entitled to impose fines of $10 000 (£8000; €9000) a day for non-compliance, penalties have never been levied.
Summary results reported
In September 2016, partly in response to low compliance and to remove ambiguity about the requirements, a clarification to the FDAAA, called the "final rule," was issued. 19 At the same time, the US National Institutes of Health (NIH) issued a policy requiring all NIH funded trials (including of interventions that are not covered by the FDAAA requirements, such as non-drug interventions) to submit registration and summary results to ClinicalTrials.gov. Compliance with this NIH policy and clarification of the FDAAA rule will need evaluation.
Posting a summary of trial results enables key information to be publicly and promptly available, including to those endeavouring to keep systematic reviews up to date. Indeed, information on participant flow, efficacy, and adverse events in trials is reported more promptly and in a higher proportion of trials in trial registries than in most reports published in journals. 20 21 It is reasonably simple to do, requires a similar format to that required for publication in a journal article, can use existing platforms, and is not regarded as prior publication by the ICMJE. Pfizer has estimated that it takes between 5 and 60 hours of person time to post a summary of the results of a completed trial to ClinicalTrials.gov. 22 Assuming an average of 40 hours at $50 per hour, the cost per trial would be about $2000. This is a trivial sum in the context of cost estimates of $42 000 per participant for running a trial. 23 Despite the benefits to trial transparency and the comparatively small time investment, ClinicalTrials.gov is currently the only public registry that has data fields to accept summary results for any registered trial. The European Clinical Trials Database also began requiring summary results in July 2014 but accepts results only of trials of drugs that are within the regulatory scope of the European Medicines Agency. It is too early to assess compliance with this requirement.
Trial protocol available
The minimum details currently required by trial registries are insufficient to enable confident interpretation and use of trial results in clinical practice. Good trial protocols facilitate full reporting and proper conduct of trials, 24 but they are not publicly available for most trials.
Inclusion of protocols in trial registries would be ideal, but this is currently rare. New regulations in the US 25 require that those conducting trials of drugs and devices (but not other interventions, such as non-drug interventions) submit a copy of the protocol and statistical analysis plan for public posting. Although this requirement is welcome, it applies to only a proportion of the world's trials and it remains to be seen whether it will be enforced. Some registries allow protocols to be uploaded as PDFs (for example, the ISRCTN registry, with ClinicalTrials.gov planning to do so this year), and others allow links to protocols published in journals or posted on other sites (for example, those for trials funded through the NIHR Health Technology Assessment Programme), but most registries do not offer either of these options.
Other trial materials
Many other trial materials that are important for interpreting, using, and replicating trials are rarely included in publications or otherwise made public. They include patient and investigator information (such as consent forms and trial information sheets), statistical analysis plans, blank case report forms, and reproducible descriptions of measurements and interventions. Ideally, these materials should be included in protocols, but this is not usual practice. Furthermore, after the protocol is complete, modifications can occur to some of this information (such as intervention details and data analysis plans) after the trial has started. Details of these modifications and updated materials should also be available.
Missing trial materials limit the interpretation and usability of results. For example, without full details, interventions shown to be useful cannot be taken up by health professionals, patients, other researchers, or policy makers. 16 Analyses have found that over half of the studies examined have incomplete descriptions of interventions (with intervention materials the most common missing component) 26 27 and that these and other trial materials are generally hard to access, even on request. 26 28 The result is that studies supported by the public and to which patients have contributed are unusable and not replicable by others, with the entire trial investment becoming a sunk cost. Another example of why access to other types of trial material can be important is the need for transparency of consent forms and patient information sheets when participants who are assigned to control groups seem to have received care below accepted standards.
Initiatives to improve access to additional materials have included guidance on descriptions of interventions 29 and public sharing platforms to facilitate sharing of trial materials, 30 but these developments have not yet received mainstream support. As with summary results, trial materials should be publicly available after the trial is completed, yet discussion is needed to agree on how to achieve this. Many registries do not accept PDF uploads, only some registries allow web links to be provided, most trials do not have websites, and links to journal online supplementary materials and other websites are often unreliable.
Clinical study reports
For some trials (usually for interventions that require regulation or licensing), clinical study reports are produced as the full trial report. Clinical study reports contain many of the elements of the trial transparency package we have described (such as detailed protocols, statistical analysis plans, and efficacy and safety evaluations). 31 As such, they can make an important contribution towards trial transparency and should be made publicly available, even if it is without the individual patient data that they sometimes contain.
All trials for all interventions
Calls to improve access to trial data tend to focus on drug, biological therapy, and medical device trials, probably because regulatory approval is required for these interventions. Despite views to the contrary, 32 these initiatives are equally important for trials of non-regulated interventions. About 40% of published randomised trials are concerned with the effects of non-regulated interventions. 33 Furthermore, trials of non-regulated interventions (such as exercise and diet; behavioural, psychological, and physical therapies; and public health interventions) are much less likely to be registered than those of regulated interventions, 
Conclusion
We believe that calls to make individual patient data available are usually made to encourage transparency and enable use, reuse, and replication of research. However, these worthy objectives will not be achieved without tackling the problems that directly stem from poor documentation and reporting of research. The potential contribution of individual patient data will remain unrealised while so much research is poorly reported, irreplicable, and uninterpretable because of selective or deceptive reporting. Trial registries are the only currently feasible mechanism by which the priorities listed here can be achieved. All registries could follow the lead of ClinicalTrials.gov and create fields for summary results to be entered. Additionally, all trialists could be required to upload protocols and other trial materials. This would make all trial information readily accessible in one location, as well as enable monitoring and reporting of compliance with providing trial information.
We strongly support efforts to improve the availability of individual patient data and acknowledge the many examples of its demonstrable value and the work of various groups towards enabling data sharing. 8 However, a more nuanced approach to increasing the availability of individual patient data may be required. For example, further work is needed to clarify what is meant by individual patient data and when and how different data types and different levels of granularity should be made available.
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Access to data from research is an important element in improving trials, particularly as permanent data loss occurs rapidly-at about 17% per year. 34 Without concurrent work on making the many other elements available, inappropriate emphasis on making individual patient data available may prove an expensive distraction, and even counterproductive. The priorities we have identified offer potentially high yield on investment-they are simple, non-controversial, require minimal changes to existing systems, and some are already required for some categories of trial. Obtaining reliable summary data for all trials offers greater public benefit than obtaining all the data for a minority of trials.
Key messages
Sharing individual participant data is an important part of trial transparency but not sufficient Simpler and more cost efficient measures to improve trial transparency and usability should be prioritised These priorities include requiring and enforcing prospective trial registration and publication of summary results, protocols, and other trial materials These priorities apply to trials of any intervention, not just to regulated interventions such as drugs and devices Without concurrent efforts on these priorities, promoting access to individual patient data may prove an expensive distraction, or even counterproductive Figure   Fig 
